MI HB5637

Amends the "Right to Try Act" to expand the definition of "investigational drug, biological product, or device" to include treatments during a COVID-19 pandemic emergency declared by the Secretary of the U.S. Department of Health and Human Services.

During a COVID-19 pandemic emergency, allows use of drugs, biological products, devices, or other treatments under investigation in FDA-approved clinical trials that a physician recommends for coronavirus disease 2019.

During a COVID-19 pandemic emergency, permits use of drugs, biological products, or devices normally prescribed for other illnesses that a physician recommends as a remedy for coronavirus disease 2019.

Adds clarifying language throughout the statute, including replacing "shall" with "must" and correcting capitalization of "United States Food and Drug Administration" terminology.

Maintains existing requirements for eligible patients, including having an advanced illness, considering all approved treatments, receiving physician recommendation, and providing written informed consent.